The Latest

  • scale
    Image attribution tooltip
    Stock via Getty Images

    Weight loss drugs: the promise and pitfalls

    GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.

  • Woman relaxing on sofa, enjoying web surfing information in internet
    Image attribution tooltip


    Sponsored by LiveWorld

    Boost returns from social strategies with new channels and tactics

    Emerging channels offer new ways to reach key targets and improve campaign ROI.

  • Teens in circle holding smart mobile phones of different colors.
    Image attribution tooltip
    Stock via Getty Images

    Patients are using social media — clinical trial experts can learn from that

    Why an alliance of industry leaders is exploring the potential of social media as a treasure trove of real-world patient experience insights. 

  • Ira Spector SFA Therapeutics
    Image attribution tooltip
    Permission granted by Ira Spector SFA Therapeutics

    A biotech CEO’s favorite ‘F’ word

    At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.

  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

  • A brown building with white vertical sign with the Twitter logo
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images

    With Twitter in flux, pharma is turning to alternative social spaces

    Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging.

  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola via Getty Images

    Economic crisis? J&J execs say that won’t stop them from hitting $60B target

    The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times.

  • Lauren Lazar Calcium
    Image attribution tooltip
    Permission granted by Lauren Lazar Calcium

    Woman of the Week: Dr. Lauren Lazar

    As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    magicmine, iStock / Getty Images Plus via Getty Images

    AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships

    A longtime leader in the respiratory space, AstraZeneca has hammered another stake in the ground with its newest asthma treatment, Airsupra.

  • High angle shot of a group of medical practitioners analyzing x-rays on a digital tablet in a hospital.
    Image attribution tooltip
    Stock via Getty Images

    Report reveals murky picture of clinical trial diversity gains

    Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas

    Already on a roll in oncology, Astellas hunts for big wins in other areas

    With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

  • A prescription bottle with white pills and a wooden gavel sit atop a $100 bill showing Benjamin Franklin's face.
    Image attribution tooltip
    Bill Oxford via Getty Images

    Drug price negotiations: 5 key dates to watch

    As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.

  • Bekki Brown UBC
    Image attribution tooltip
    Permission granted by Bekki Brown
    Q&A // First 90 Days

    UBC crowns Bekki Brown as its new CEO with a clear mandate to grow

    The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.

  • Novavax vaccine
    Image attribution tooltip
    Carsten Koall via Getty Images

    After ‘limping along,’ Novavax sees a path forward

    With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.

  • The headquarters of the FDA, which has recently issued a recall for Teleflex air filters used in hospital respirators.
    Image attribution tooltip
    Sarah Silbiger/Getty Images via Getty Images

    FDA’s 2022 drug approvals fall short of recent norms

    The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.

  • Sean McCarthy, CEO and chairman, CytomX
    Image attribution tooltip
    Permission granted by CytomX

    A Moderna tie-up ushers in new era for CytomX

    The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

  • Talia Cohen-Solal Genetika+
    Image attribution tooltip
    Permission granted by Talia Cohen-Solal WoW

    Woman of the Week: Genetika+’s Talia Cohen Solal

    The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

  • Viewed from above, a rendering of the COVID-19 virus sits in the center of a clay, red basketball court.
    Image attribution tooltip
    Enes Evren via Getty Images

    Pro sports’ COVID protocols led to real-world data impacts for pharma

    After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    JuSun via Getty Images

    The M&A hunt is on — here are the prime targets

    Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.

  • financial storm
    Image attribution tooltip
    Stock via Getty Images

    How biotechs can weather the market storm

    Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

  • International Space Station
    Image attribution tooltip
    iStock via Getty Images

    Space — the next frontier in drug development

    Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

  • M&A handshake
    Image attribution tooltip
    iStock via Getty Images

    Biopharma M&A may get the push it needs in 2023, but with a face lift

    A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

  • Hans Schambye Galecto
    Image attribution tooltip
    Permission granted by Hans Schambye
    Q&A // Biotech Spotlight

    Galecto has identified a master switch to reduce fibroid formation

    With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

  • Claire Aldridge Form Bio
    Image attribution tooltip
    Permission granted by Claire Aldridge Form Bio

    Woman of the Week: Form Bio’s Claire Aldridge

    The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

  • Kidney
    Image attribution tooltip
    iStock via Getty Images
    Biotech Spotlight

    Chinook Therapeutics nears the finish line in kidney disease

    A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

  • A photograph of a Biogen building located in Cambridge, Massachusetts, on Oct. 22, 2015.
    Image attribution tooltip

    Nicolaus Czarnecki/Zuma Press/Newscom

    Making Moves

    C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans

    A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.